mCRPC in focus
Transcript: CONTACT-02
Dr Silke Gillessen
Interview recorded September 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
The CONTACT-02 study, was also a study in the mCRPC setting, was presented by Neeraj Agarwal, who, the question was, you know, if the combination of cabozantinib plus atezolizumab versus a second RP was beneficial. He had presented the data already at ASCO GU, so there was a benefit in FPFS, and what he showed at ESMO is that there was no difference in overall survival. So I guess, you know, a lot of people already were discussing, you know, the value of the control arm because of course, it's very much discussed if a second RP is the right option.
So I personally have the opinion that a second RP, we know there's a lot of cross-resistance, and it's only very selected patients who may profit from it. And in that study, in comparison to other study, like the SPLASH study that was also presented at ESMO, this was not selected patients because there were also patients with liver metastasis. Usually, I guess most of us would not give a second RP in that situation, so in the end, probably a combination that will not be approved by any agency, but we will see.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.